# Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis

> **NCT03523221** · PHASE1 · RECRUITING · sponsor: **Hamad Medical Corporation** · enrollment: 210 (estimated)

## Conditions studied

- Anaphylaxis

## Interventions

- **DRUG:** Dexamethasone Oral

## Key facts

- **NCT ID:** NCT03523221
- **Lead sponsor:** Hamad Medical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-04-15
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2024-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03523221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03523221, "Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03523221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*